Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of NA-831 in Alzheimer Patients With Mild Cognitive Impairment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 May 2023
Price :
$35
*
At a glance
- Drugs Traneurocin (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Adverse reactions; Therapeutic Use
- Sponsors NeuroActiva
- 18 May 2023 According to a Biomed Industries media release, results from this trial were presented at the Alzheimer's Association International Conference 2022
- 18 May 2023 According to a Biomed Industries media release, results from this trial were presented at the Alzheimer's Disease/Parkinson's Disease International Conference 2023.
- 18 May 2023 Results presented in the Biomed Industries Media Release.